We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dermatitis and eczema
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Aims: To understand what influences clinicians and patients in using a novel, cheap treatment for managing eczema (The Combined Approach - TCA), and what changes are needed to improve its use.
Background: Eczema is painful, can lead to infections, has a negative effect on quality of life and high costs for the health service. A key problem in eczema is itch, which makes people scratch, leading to further itch and scratch. Patients have described itch as ‘the bane of my life’. TCA is novel as it includes both treating the skin with medications and also helping people manage their scratch behaviour with habit reversal. It has shown good results in several small studies, but it hasn’t been used much in practice. It is important to understand this before future research is done.
Methods
We will send a survey through Eczema Outreach Support (EOS) and the National Eczema Association (NES) to ask people with eczema their thoughts on TCA, and through professional organisations to gather health care professionals’ (HCPs) views. We will interview up to twenty patients and twenty HCPs, including people who both like and don’t like the idea of TCA. We will analyse the results to understand why people do or don’t use TCA, and if it could be improved. We will then hold a meeting to see if and how we should improve and further research TCA.
PPI
We are collaborating with EOS and the NES who think this is an important topic and we have spoken with individuals with AD who helped us write our application. Patients and the public will collaborate in design of the survey, topic guides, the workshop and interpretation of results, and dissemination.
Dissemination
We will publish our results and present at patient forums and conferences.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Qualitative;
You can take part if:
You may not be able to take part if:
i) Health Care Professional • Not prepared to give consent • Has not practised within the UK healthcare setting • Inability to understand written and/or verbal English ii) People with Atopic Dermatitis • Other form of dermatitis such as seborrheic dermatitis • Child under the age of 13 • Lacking capacity to give informed consent • Inability to understand written and/or verbal consent
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by BARTS HEALTH NHS TRUST and funded by NIHR Central Commissioning Facility (CCF) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 57239
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
